Mesa Labs Posts 75c Q2 EPS as Operating Income Jumps 78%
MLAB sits 76% above its 52-week low of $69.51.
Summary
Mesa Labs reported second-quarter EPS of 75 cents, landing alongside a 10-Q filed minutes earlier showing revenue up 2.6% to $62.3M and operating income up 77.6% to $8.4M. The profit growth is the story here: operating leverage is kicking in on flat-to-modest sales, and the company paired it with a new $40M buyback authorization. This follows the October restructuring that cut about 40 positions, roughly 6% of the workforce, to save $9.3M a year — the margin improvement is the first hard evidence those cuts are flowing through. Management also issued FY27 guidance for the first time in the 8-K, guiding FY2027 EBITDA growth of 5%–8%, which gives the Street a formal bar to measure against. Watch the goodwill impairment tied to Clinical Genomics weakness flagged in the 10-Q — that is the offsetting risk to an otherwise clean quarter.
At the time of this announcement, MLAB was trading at $122.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $715.3M. The 52-week trading range was $69.51 to $144.35. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.